A Phase II Trial of Didemnin B (NSC #335319) in Patients with Previously Treated Epithelial Ovarian Cancer A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199302000-00012 ◽

1993 ◽

Vol 16 (1) ◽

pp. 47-49 ◽

Author(s):

John H. Malfetano ◽

John A. Blessing ◽

Allan J. Jacobs

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Previously Treated

Download Full-text

A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/0090-8258(92)90055-n ◽

1992 ◽

Vol 44 (3) ◽

pp. 268-270 ◽

Author(s):

Allan J. Jacobs ◽

John A. Blessing ◽

Alan Munoz

Keyword(s):

Cervical Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.035 ◽

2012 ◽

Vol 124 (3) ◽

pp. 563-568 ◽

Author(s):

Leslie M. Randall ◽

Michael W. Sill ◽

Robert A. Burger ◽

Bradley J. Monk ◽

Barbara Buening ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Predictive Value ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Ca 125 ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Cancer

Download Full-text

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.5009 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 5009-5009 ◽

Author(s):

R. A. Burger ◽

M. Sill ◽

B. J. Monk ◽

B. Greer ◽

J. Sorosky

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text

A Phase II Trial of Ifosfamide and Mesna in Patients with Advanced or Recurrent Mixed Mesodermal Tumors of the Ovary Previously Treated with Platinum-Based Chemotherapy: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.1994.1081 ◽

1994 ◽

Vol 53 (1) ◽

pp. 24-26 ◽

Author(s):

Gregory P. Sutton ◽

John A. Blessing ◽

Howard D. Homesley ◽

John H. Malfetano

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Based Chemotherapy ◽

Previously Treated

Download Full-text

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6441 ◽

2002 ◽

Vol 84 (1) ◽

pp. 32-35 ◽

Author(s):

Steven C. Plaxe ◽

John A. Blessing ◽

Michael A. Bookman ◽

William T. Creasman

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive

Download Full-text

Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.5537 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 5537-5537 ◽

Author(s):

D. Matei ◽

M. W. Sill ◽

K. DeGeest ◽

R. E. Bristow

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text

A Phase II Trial of Gallium Nitrate (NSC #15200) in Previously Treated Ovarian Carcinoma A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199108000-00015 ◽

1991 ◽

Vol 14 (4) ◽

pp. 349-351 ◽

Author(s):

John H. Malfetano ◽

John A. Blessing ◽

Mark D. Adelson

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gallium Nitrate ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Previously Treated

Download Full-text

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.06.017 ◽

2018 ◽

Vol 150 (3) ◽

pp. 466-470 ◽

Author(s):

Robert A. Burger ◽

Wei Deng ◽

Vicky Makker ◽

Yvonne Collins ◽

Heidi Gray ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70331-2 ◽

2007 ◽

Vol 2007 ◽

pp. 82-83

Author(s):

J.T. Thigpen

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Faculty Opinions recommendation of Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969752.793471344 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text